menu
    • menu

    Company profile for Regeneron Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Regeneron is a leading science and technology company delivering life-transforming medicines for serious diseases. Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in four FDA-approved medicines and numerous product candidates in a range of diseases, including ophthalmology, rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases.In addition to our med...
    Regeneron is a leading science and technology company delivering life-transforming medicines for serious diseases. Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in four FDA-approved medicines and numerous product candidates in a range of diseases, including ophthalmology, rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases.In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human genetics sequencing efforts in the world

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Regeneron PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    777 Old Saw Mill River Road Tarrytown, NY 10591
    Telephone
    Telephone
    +1 914-847-7000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.regeneron.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company-beta/13476?pathWildcard=13476
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/regeneron

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alvotech, Teva Set U.S. Date For AVT06, Biosimilar To Eylea
    Alvotech, Teva Set U.S. Date For AVT06, Biosimilar To Eylea

    19 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/19/3208323/0/en/Alvotech-and-Teva-Secure-U-S-Settlement-Date-for-AVT06-a-Proposed-Biosimilar-to-Eylea.html

    GLOBENEWSWIRE
    19 Dec 2025
    Share Share
    Regeneron Rebounds Post Regulatory & Manufacturing Challenges
    Regeneron Rebounds Post Regulatory & Manufacturing Challenges

    10 Dec 2025

    // BIOSPACE

    https://www.biospace.com/business/regeneron-climbs-back-after-a-year-of-regulatory-manufacturing-misery

    BIOSPACE
    10 Dec 2025
    Share Share
    ASH: Regeneron eyes simpler regimens to grow bispecifics' reach
    ASH: Regeneron eyes simpler regimens to grow bispecifics' reach

    08 Dec 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/ash-regeneron-does-subtraction-bids-move-bispecifics-earlier-treatment-blood-cancers

    FIERCE PHARMA
    08 Dec 2025
    Share Share
    Lynozyfic Shows Strong Responses in NDMM Patients
    Lynozyfic Shows Strong Responses in NDMM Patients

    07 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/07/3201147/0/en/Lynozyfic-linvoseltamab-Monotherapy-in-Newly-Diagnosed-Multiple-Myeloma-NDMM-Shows-Impressive-Responses-Supporting-Rationale-as-a-Potential-Foundation-in-Frontline-Treatment.html

    GLOBENEWSWIRE
    07 Dec 2025
    Share Share
    Regeneron Inks $150 M Pact with Gene Writer Tessera
    Regeneron Inks $150 M Pact with Gene Writer Tessera

    01 Dec 2025

    // PRESS RELEASE

    https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-tessera-therapeutics-jointly-develop-tsra-196

    PRESS RELEASE
    01 Dec 2025
    Share Share
    EU Approves Dupixent As First Targeted Drug For Chronic Urticaria
    EU Approves Dupixent As First Targeted Drug For Chronic Urticaria

    26 Nov 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-11-25-06-00-00-3194015

    PRESS RELEASE
    26 Nov 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

    Details:

    Kevzara (Sarilumab) is a antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Polymyalgia Rheumatica.


    Lead Product(s): Sarilumab,Inapplicable

    Therapeutic Area: Musculoskeletal Brand Name: Kevzara

    Study Phase: Phase IVProduct Type: Antibody, Unconjugated

    Recipient: Sanofi

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 16, 2025

    blank

    01

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sarilumab,Inapplicable

    Therapeutic Area : Musculoskeletal

    Highest Development Status : Phase IV

    Recipient : Sanofi

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

    Details : Kevzara (Sarilumab) is a antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Polymyalgia Rheumatica.

    Product Name : Kevzara

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    December 16, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

    Details:

    Oxaliplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Colorectal Neoplasms.


    Lead Product(s): Oxaliplatin,Capecitabine,Cemiplimab,Fianlimab,REGN7075

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Cytotoxic Drug

    Recipient: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 15, 2025

    blank

    02

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Oxaliplatin,Capecitabine,Cemiplimab,Fianlimab,REGN7075

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Recipient : Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Loca...

    Details : Oxaliplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Colorectal Neoplasms.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    December 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

    Details:

    ALN-ANG3 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Diabetic Nephropathies.


    Lead Product(s): ALN-ANG3,Evinacumab

    Therapeutic Area: Nephrology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 09, 2025

    blank

    03

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ALN-ANG3,Evinacumab

    Therapeutic Area : Nephrology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participa...

    Details : ALN-ANG3 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Diabetic Nephropathies.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    December 09, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regeneron, Tessera to Develop TSRA-196 Gene Editing Therapy for AATD

    Details:

    The collaboration aims to advance TSRA-196, a cell & gene therapy, targeting A1AT for Alpha-1 Antitrypsin Deficiency (AATD).


    Lead Product(s): TSRA-196,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy

    Recipient: Tessera Therapeutics

    Deal Size: $275.0 million Upfront Cash: $150.0 million

    Deal Type: Collaboration December 01, 2025

    blank

    04

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : TSRA-196,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I/ Phase II

    Recipient : Tessera Therapeutics

    Deal Size : $275.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Regeneron, Tessera to Develop TSRA-196 Gene Editing Therapy for AATD

    Details : The collaboration aims to advance TSRA-196, a cell & gene therapy, targeting A1AT for Alpha-1 Antitrypsin Deficiency (AATD).

    Product Name : Undisclosed

    Product Type : Cell & Gene Therapy

    Upfront Cash : $150.0 million

    December 01, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma

    Details:

    Cemiplimab is a antibody candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Basal Cell.


    Lead Product(s): Cemiplimab,Imiquimod

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated

    Recipient: Instituto Oncológico Dr. Rosell

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 26, 2025

    blank

    05

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cemiplimab,Imiquimod

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Recipient : Instituto Oncológico Dr. Rosell

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carci...

    Details : Cemiplimab is a antibody candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Basal Cell.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 26, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Dupixent® Approved as First Targeted Medicine in EU for Chronic Spontaneous Urticaria

    Details:

    Dupilumab, an unconjugated antibody targeting Interleukin-4 receptor subunit alpha, shows promise in treating undisclosed Key Focus Area.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Immunology Brand Name: Dupixent

    Study Phase: Approved FDFProduct Type: Antibody, Unconjugated

    Sponsor: Sanofi

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 25, 2025

    blank

    06

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Sanofi

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Dupixent® Approved as First Targeted Medicine in EU for Chronic Spontaneous Urticaria

    Details : Dupilumab, an unconjugated antibody targeting Interleukin-4 receptor subunit alpha, shows promise in treating undisclosed Key Focus Area.

    Product Name : Dupixent

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 25, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

    Details:

    REGN4461 (Mibavademab) is an antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Functional Hypothalamic Amenorrhea.


    Lead Product(s): Mibavademab,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: REGN4461

    Study Phase: Phase IIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 19, 2025

    blank

    07

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mibavademab,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

    Details : REGN4461 (Mibavademab) is an antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Functional Hypothalamic Amenorrhea.

    Product Name : REGN4461

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Fda Approves Eylea Hd® 8 mg for Macular Edema and Monthly Dosing

    Details:

    Aflibercept, a protein targeting vascular endothelial growth factor A and placenta growth factor, shows promise in treating macular edema.


    Lead Product(s): Aflibercept,Inapplicable

    Therapeutic Area: Ophthalmology Brand Name: Eylea HD

    Study Phase: Approved FDFProduct Type: Protein

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 19, 2025

    blank

    08

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Aflibercept,Inapplicable

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Fda Approves Eylea Hd® 8 mg for Macular Edema and Monthly Dosing

    Details : Aflibercept, a protein targeting vascular endothelial growth factor A and placenta growth factor, shows promise in treating macular edema.

    Product Name : Eylea HD

    Product Type : Protein

    Upfront Cash : Inapplicable

    November 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Libtayo® Approved in EU as First Immunotherapy for Adjuvant Treatment of CSCC

    Details:

    Cemiplimab, an antibody targeting PD-1, shows promise in treating cutaneous squamous cell carcinoma (CSCC).


    Lead Product(s): Cemiplimab,Inapplicable

    Therapeutic Area: Oncology Brand Name: Libtayo

    Study Phase: Approved FDFProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 19, 2025

    blank

    09

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cemiplimab,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Libtayo® Approved in EU as First Immunotherapy for Adjuvant Treatment of CSCC

    Details : Cemiplimab, an antibody targeting PD-1, shows promise in treating cutaneous squamous cell carcinoma (CSCC).

    Product Name : Libtayo

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

    Details:

    Cemiplimab is an antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Mesothelioma, Malignant.


    Lead Product(s): Cemiplimab,Fianlimab,Pemetrexed,Cisplatin,Carboplatin

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody, Unconjugated

    Recipient: Intergroupe Francophone de Cancerologie Thoracique

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 18, 2025

    blank

    10

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Regeneron Pharmaceuticals

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cemiplimab,Fianlimab,Pemetrexed,Cisplatin,Carboplatin

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Recipient : Intergroupe Francophone de Cancerologie Thoracique

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Pat...

    Details : Cemiplimab is an antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Mesothelioma, Malignant.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Regeneron Pharmaceuticals and get a quotation

    Regeneron Pharmaceuticals is a supplier offers 20 products (APIs, Excipients or Intermediates).

    Find a price of Cemiplimab bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Dupilumab bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium / Medium Additives / RCDF2v2 stock fed solution bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium / Medium Additives / RCDF2v3 stock fed solution bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium / Medium Additives / CDM1B. C13 Production Bioreactor Medium bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium / Medium Additives / RCDF2D stock fed solution bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium/medium additive ・RCDF1 stock feed solution bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium/medium additive ・RCDF4 stock feed solution bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium/Medium additives・RS5 30X stock feed solution bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium/medium additives/CDM1B. C13 Production Bioreactor Medium bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Media/Media Additives CDM1B. C13 Cell Culture Medium bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Media/Media Additives CDM1B. C13 Production Bioreactor Medium bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium/Medium additives・RCDF7V2 Stock Feed Solution bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium / Medium Additives-CDM1B. C13 Production Bioreactor Medium bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium / Medium Additives-CDM1B. C13 Seed Train Medium bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium / Medium Additives / CDM1B. C13 Seed Train Medium bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium/medium additive ・RCDF5 stock feed solution bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Cells/Evinacumab Development Cell Bank bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of Medium/Medium additives・RCDF7 Stock Feed Solution bulk with JDMF offered by Regeneron Pharmaceuticals

    Find a price of RILONACEPT bulk offered by Regeneron Pharmaceuticals

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search